Study
| Double-blind, placebo-controlled phase 3 trial (MAGNITUDE) |
| Previously untreated, CRPC |
| Abirateron acetate + Niraparib (n=212) vs. Abiraterone acetate + PBO (n=211) |
Efficacy
| BRCAmutated: mrPFS: 16.6 vs. 10.9 mos, HR:0.45, p=0.0003 |
| HRR +: mrPFS: 16.5 vs.13.7 mos, HR: 0.73, P=0.022 |
| HRR+ and nonBRCA: HR:0.99 [0.68-1.44] for rPFS |
Safety
| Grade≥3 AEs: Anemia (29.7% vs. 28.0%), hypertension (14.6% vs. 12.3%), thrombocytopenia (6.6% vs. 2.4%) |
J Clin Oncol 2023 41:18, 3339-3351
http://doi.org/10.1200/JCO.22.01649
Reviewed by Elvin CHALABİYEV, MD on SEP 10, 2023
